| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| 99213 |
Office or other outpatient visit for the evaluation and management of an established patient, low complexity |
16,488 |
15,941 |
$1.87M |
| 99214 |
Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity |
14,159 |
13,802 |
$1.60M |
| 99203 |
Office or other outpatient visit for the evaluation and management of a new patient, low complexity |
13,880 |
13,564 |
$1.58M |
| 99204 |
Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity |
3,156 |
3,109 |
$375K |
| 99202 |
Office or other outpatient visit for the evaluation and management of a new patient, straightforward |
1,157 |
1,116 |
$126K |
| 87880 |
Infectious agent antigen detection by immunoassay; Streptococcus, group A |
5,780 |
5,519 |
$13K |
| 99215 |
Prolong outpt/office vis |
112 |
111 |
$13K |
| 99000 |
|
1,940 |
1,879 |
$2K |
| 94640 |
Pressurized or nonpressurized inhalation treatment for acute airway obstruction |
234 |
224 |
$630.02 |
| 87426 |
Infectious agent antigen detection, SARS-CoV-2 (COVID-19) |
80 |
74 |
$614.63 |
| 69210 |
|
12 |
12 |
$293.95 |
| 96372 |
Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular |
82 |
79 |
$193.83 |
| 94664 |
|
81 |
75 |
$122.89 |
| J1100 |
Injection, dexamethasone sodium phosphate, 1 mg |
287 |
274 |
$109.59 |
| 94760 |
|
697 |
683 |
$22.48 |
| J0696 |
Injection, ceftriaxone sodium, per 250 mg |
13 |
12 |
$14.90 |
| J7613 |
Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 1 mg |
197 |
193 |
$5.59 |
| J7510 |
Prednisolone oral, per 5 mg |
76 |
74 |
$3.05 |
| J7644 |
Ipratropium bromide, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose form, per milligram |
40 |
39 |
$0.44 |
| J2405 |
Injection, ondansetron hydrochloride, per 1 mg |
29 |
27 |
$0.36 |
| 99051 |
|
31 |
29 |
$0.00 |